Cardiovascular Financial News

avoid visiting places with high air pollution levels. These areas may include "slow and heavy traffic roads and areas near polluting industries, construction, demolition sites etc".

Delhi health department has advised a slew of measures in view of the pollution in the national capital. The advisory, published in major dailies on Saturday has also underlined that pregnant women, patients with underlying medical conditions, children and the elderly population should be more cautious and avoid exposure to air pollution. However, intermittent rains on Thursday night and Friday brought major relief from the hazardous air lingering over the national capital for two weeks.

There is hope for those of us who live (and sleep) in the real world: Getting less than 8 hours of shut-eye a night doesn’t mean you’re doomed to an early grave. A recent study looking at sleep and longevity found that sleep “regularity"—going to bed and waking up at consistent times with few mid-slumber interruptions—matters more than how long you sleep. Sleeping six hours every night on a consistent schedule was associated with a lower risk of early death than sleeping eight hours with very irregular habits.

₹366 crore. The acquired units, encompassing more than 20 major brands, reported a turnover of ₹90 crore in fiscal year 2023, with a current revenue run-rate of ₹100 crore. The deal, which includes the transfer of working capital, will see over 120 personnel, including senior leaders and field staff, transition to Eris Lifesciences.

Eris Lifesciences on Wednesday said it has entered into a definitive agreement to acquire Biocon Biologics' dermatology and nephrology branded formulations business units in India for Rs 366 crore. Eris said the acquisition will be funded partly through debt financing. The deal is inclusive of working capital and the key leadership and entire field force of this business, consisting of over 120 personnel of Biocon Biologics' nephro and derma units are expected to move to Eris post deal. The transaction is expected to close by the end of November 2023. The business includes over 20 mother brands with FY23 Revenue of Rs 90 cr. and current revenue run-rate of Rs 100 crore. Some of the legacy brands include Tacrograf and Renodapt in organ transplants and emerging brands like Bionesp and Erypro in chronic kidney disease — induced anaemia.

By Jacob Gronholt-Pedersen

Say goodbye to compromising on quality and hello to a healthier, fitter you. With the top-rated cross trainers, you'll experience workouts like never before, minimizing the risk of injury and maximizing your progress. Don't wait any longer; invest in the best and redefine your fitness goals today.

Biotechnology giant CSL argues an ageing population will help shield its business from any fallout from the explosion in Ozempic-style drugs used off-label to treat weight loss, and potentially undermining its investment in therapies targeting kidney disease.

Medtronic is seeking to streamline its portfolio and focus on its higher-growth assets, such as its heart and diabetes devices, by divesting the two units which generated approximately $2.2 billion in revenue in the 2022 fiscal year according to the company. The businesses that Medtronic would shed would be moved to a new company majority-owned by Carlyle, the sources said. Medtronic would retain a stake in the new company of more than 35%, the sources added.

In a country, where cardiovascular diseases have turned into a silent epidemic of sorts, and account for at least 27 per cent of deaths, the matter of taking utmost care of heart health is more important than ever. Every year, World Heart Day is observed on September 29. On this day, several healthcare providers work along with government and international organisations to promote awareness about various types of cardiovascular diseases, as well as the myriad lifestyle habits and poor diets that contribute to the deterioration of heart health.

Edwards Lifesciences (NYSE:EW) was raised to Outperform from Perform with a $90 per share price target by Oppenheimer analyst on Tuesday.

MUMBAI : Nirma Ltd has agreed to buy 75% of Glenmark Life Sciences Ltd for ₹5,651.5 crore in a deal that values the latter at ₹7,535.4 crore. Mint reported first on 15 August that the cement-to-detergent maker was the sole bidder for the stake put on the block by parent Glenmark Pharmaceuticals Ltd, which is selling shares to Nirma at ₹615 apiece. Glenmark Pharma will continue to own 7.84% of Glenmark Life Sciences.

reducing anaemia have failed to substantially reduce the massive burden of anaemia globally over the last few decades. People become anemic when their blood lacks enough healthy red blood cells to carry oxygen throughout the body. This decreased oxygen delivery causes many of the most common symptoms of anaemia, including fatigue, shortness of breath, lightheadedness, difficulty concentrating and challenges with work and daily life tasks. In addition to its direct health effects, anaemia can inhibit brain development and fine motor skills in children and heighten the risk of stroke, cardiovascular disease, dementia and other chronic illnesses in older adults. Anaemia during pregnancy can lead to increased rates of anxiety and depression, early labour, postpartum hemorrhage, stillbirth and low birth weight. Infections for both mother and baby are also more likely when the mother is anemic. We are global health researchers with expertise in epidemiological modeling of anaemia alongside other maternal, neonatal and nutritional disorders. Our work is part of the Global Burden of Disease Study, a large research study comprehensively estimating health loss due to hundreds of diseases, injuries and risk factors around the globe. Through our analysis, we have produced annual estimates of anaemia prevalence by underlying cause for 204 countries and territories, by age and sex, from 1990 to the present. We have collected thousands of data points across hundreds of sources to produce the most comprehensive picture of anaemia burden.

Reliance Industries: Reliance Retail Ventures Limited announced today that global investment firm KKR, through an affiliate, will invest ₹ 2,069.50 crore into RRVL, a subsidiary of Reliance Industries Limited. This investment values RRVL at a pre-money equity value of ₹ 8.361 lakh crore, which makes it among the top four companies by equity value in the country.

release from TCS, the project will create groundbreaking medical solutions like the use of heart simulation as a source of digital evidence for new cardiovascular device approvals. The project includes in-silico clinical trials that could complement the evidence drawn from clinical subjects while reducing the need for animal testing and human enrollment for clinical trials, the release added.

Tata Consultancy Services on Monday said it joined the Living Heart Project of European technology major Dassault Systemes to create accurate digital human heart models. TCS in an exchange filing said it will use its domain and technology expertise, and research on the Digital BioTwin of the heart to contribute to model refinement, simulation, and technological implementation in developing and validating accurate and personalised digital human heart models. The TCS Digital BioTwin is a biophysics-based high-fidelity computational model developed by TCS researchers to enable the investigation of the function of a particular human organ remotely and non-invasively.

A team of researchers from the University of Cincinnati has developed a new device that can warn people about the early risks of tooth decay due to diseases like gingivitis and periodontitis.

The majority of these occurred in people 65 and older — the age group with the highest risk for cardiovascular complications. But heart-related deaths also increased dramatically in younger adults. In fact, a study found that the sharpest rise in deaths from heart attack during that period occurred in 25- to 44-year-olds. Some of these cardiovascular-related fatalities may have happened because it was harder to access medical care during the height of the pandemic. But physicians and researchers now have little doubt that COVID-19 itself was a factor. In addition to the complications that can occur during the acute phase of a COVID infection, there appears to be an increased risk of heart attacks, strokes and other problems up to a year after an infection. Experts are now trying to understand why. «There's a very unique connection between this virus and the cardiovascular system,» said Dr. Susan Cheng, the chair of cardiovascular health and population science at Cedars-Sinai, who led the study on heart attack deaths. «What is that connection? That's the million-dollar question.»

climate change, it coincided with the spread of uncommon diseases as well. Health experts in the US have warned of the health consequences of not addressing climate change. Malaria, a disease of tropical regions and other warmer areas was detected in Texas and Florida. These are also the states that have registered record temperatures, as per reports.

India — Covishield and Covaxin — and increase in the risk of heart attacks, according to an observational study which emphasises the protective effect of the jabs. The research, published recently in the journal PLOS One, determined the impact of COVID-19 vaccination on mortality following acute myocardial infarction (AMI) or heart attack.

heart attack. The retrospective study used data from 1,578 people admitted to G B Pant hospital in Delhi between August 2021 and August 2022. As many as 1,086 (68.8 per cent) were vaccinated against COVID-19 while 492 (31.2 per cent) were unvaccinated. Among the vaccinated group, 1,047 (96 per cent) had received two doses of the vaccine while 39 (4 per cent) had received only a single dose. «Our study found that vaccines used in India are safe.